Turn Therapeutics Inc. — Form 8-K
Filed November 10, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Turn Therapeutics, a $17M-asset biotech, disclosed Phase 2a interim results for GX-03 (IL-36/IL-31 inhibitor topical) in moderate-to-severe atopic dermatitis. In an enriched subgroup (n=25, baseline pruritus NRS≥7), GX-03 achieved 61.5% Week 4 vIGA success vs 8.3% vehicle (Δ53.2%, p~0.012). Phase 2b expansion (~120–136 patients) is enrolling with topline expected Q1 2027; Phase 3 planned mid-2027. Company also plans Phase 3 for onychomycosis (Q2 2027 initiation) and Phase 2a for hidradenitis suppurativa (Q1 2027). Cash runway extends to Q3 2027 (~$10.4M as of Sept 30, 2026); $1M/quarter burn.
Why this rating
Phase 2 data shows promising efficacy signal (53% treatment difference on primary endpoint) in a large, unmet-need indication (6.6M US moderate-severe AD patients; $9.6B TAM). Interim results de-risk regulatory path and support planned Phase 3, a material value inflection for a $17M company. However, small phase size, enriched population, and early-stage development limit certainty. Positive clinical readout moves needle on company trajectory meaningfully.
Tradability signal
NO TRADE
No trade: positive news with only -1.5% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.40% over 4 hrs, n=417). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $9.72 | +10 min · unknown $9.63 ▼ 0.93% | +30 min · unknown $9.93 ▲ 2.16% | +1 hr · unknown $10.09 ▲ 3.76% | +4 hrs · unknown $9.74 ▲ 0.26% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.